<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00461617</url>
  </required_header>
  <id_info>
    <org_study_id>KAD1301</org_study_id>
    <nct_id>NCT00461617</nct_id>
  </id_info>
  <brief_title>Double-Blind Comparison Between Mitiglinide and Nateglinide in Type 2 Diabetic Patients</brief_title>
  <official_title>Multicentre, Double-Dummy, Randomized, Double-Blind Comparison Between Mitiglinide and Nateglinide in the Patients With Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kissei Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kissei Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of Mitiglinide compared to
      Nateglinide for the treatment of type 2 diabetes.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2006</start_date>
  <completion_date type="Actual">July 2007</completion_date>
  <primary_completion_date type="Actual">July 2007</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hemoglobin A1C (HbA1C)</measure>
    <time_frame>-2, 0, 4, 8, 10, 12, 16, 20 week</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Fasting plasma glucose level (FPG)</measure>
    <time_frame>0, 4, 8, 12, 16, 20 week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Two-hour postprandial glucose level (PPG2)</measure>
    <time_frame>0, 12, 20 week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>One-hour postprandial glucose level (PPG1)</measure>
    <time_frame>0, 12, 20 week</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">291</enrollment>
  <condition>Diabetes</condition>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Nateglinide 120 mg TID</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mitiglinide</intervention_name>
    <description>10mg tablet, 10mg TID</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Glufast</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Type 2 diabetes patients with inadequate control of blood glucose with diet and/or
             exercise therapy

        Exclusion Criteria:

          -  Type 1 diabetes patients

          -  Patients who require treatment with insulin

          -  Patients with severe diabetic complications (neuropathy, retinopathy or nephropathy)

          -  Patients with severe ketosis, diabetic coma or precoma

          -  Patients complicated with severe hepatic diseases

          -  Patients complicated with severe renal diseases

          -  Patients complicated with severe hypertension

          -  Patients complicated with severe cardiac disease

          -  Pregnant women or women possible to be pregnant, nursing women, or women who want to
             become pregnant during the study period
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xin Gao, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Endocrinology Dept. of Fudan University Zhongshan Hospital</affiliation>
  </overall_official>
  <verification_date>April 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 17, 2007</study_first_submitted>
  <study_first_submitted_qc>April 17, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 18, 2007</study_first_posted>
  <last_update_submitted>October 20, 2008</last_update_submitted>
  <last_update_submitted_qc>October 20, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 21, 2008</last_update_posted>
  <responsible_party>
    <name_title>Gao Xin/Professor</name_title>
    <organization>Zhongshan Hospital, Fudan University</organization>
  </responsible_party>
  <keyword>diabetes</keyword>
  <keyword>rapid and short acting insulin secretagogue</keyword>
  <keyword>Î±-glucosidase inhibitor</keyword>
  <keyword>HbA1C</keyword>
  <keyword>insulin</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nateglinide</mesh_term>
    <mesh_term>Mitiglinide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

